Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
Boehringer Ingelheim
Harvard Business School
Merck

Last Updated: August 15, 2022

SESQUIENT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Sesquient, and when can generic versions of Sesquient launch?

Sesquient is a drug marketed by Lupin and is included in one NDA. There are five patents protecting this drug.

This drug has fifty-one patent family members in fourteen countries.

The generic ingredient in SESQUIENT is fosphenytoin sodium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sesquient

A generic version of SESQUIENT was approved as fosphenytoin sodium by ATLANTIDE on August 6th, 2007.

  Try it Free

US Patents and Regulatory Information for SESQUIENT

SESQUIENT is protected by five US patents.

Patents protecting SESQUIENT

Sulfoalkyl ether cyclodextrin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sulfoalkyl ether cyclodextrin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sulfoalkyl ether cyclodextrin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Alkylated cyclodextrin compositions and processes for preparing and using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Sulfoalkyl ether cyclodextrin compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-002 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-002 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Lupin SESQUIENT fosphenytoin sodium SOLUTION;INTRAVENOUS 210864-001 Nov 5, 2020 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SESQUIENT

See the table below for patents covering SESQUIENT around the world.

Country Patent Number Title Estimated Expiration
Australia 2016210707 Alkylated cyclodextrin compositions and processes for preparing and using the same See Plans and Pricing
South Korea 20200106100 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 (Alkylated Cyclodextrin Compositions and Processes for Preparing and using the same) See Plans and Pricing
Australia 2013226073 Alkylated cyclodextrin compositions and processes for preparing and using the same See Plans and Pricing
Mexico 2010004900 COMPOSICIONES DE ETER-SULFOALQUILICO-CICLODEXTRINA. (SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS.) See Plans and Pricing
Japan 2010539193 See Plans and Pricing
Japan 4923144 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SESQUIENT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0473687 3/1999 Austria See Plans and Pricing PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
0473687 SPC/GB98/030 United Kingdom See Plans and Pricing PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0473687 99C0008 Belgium See Plans and Pricing PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
0145340 99C0005 Belgium See Plans and Pricing PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
0473687 C980045 Netherlands See Plans and Pricing PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
McKesson
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.